Credit Suisse’s Mustang Bio MBIO Stock Holding History

Credit Suisse’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13	Closed	-$17K	–	4033
2021 Q4	$17K	Buy	+13	New	+$21K	﹤0.01%	4452
2021 Q1	–	Sell	-20	Closed	-$57K	–	4460
2020 Q4	$57K	Buy	+20	New	+$47.8K	﹤0.01%	4243

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse's MBIO Position: Q1 2022 in Review

Credit Suisse sold out of Mustang Bio (MBIO) in Q1 2022, closing a stake of 13 shares — an estimated $17K sold.

Credit Suisse first reported a position in MBIO in Q4 2020 and held it in 2 quarters. The position peaked at $57K in Q4 2020. 81 funds tracked by Wall St. Rank hold MBIO as of Q1 2022.

Credit Suisse reported no remaining Mustang Bio position as of Q1 2022 after selling out during the quarter.
Credit Suisse sold 13 Mustang Bio shares in Q1 2022, an estimated $17K.
Credit Suisse first reported a position in Mustang Bio in Q4 2020 and held it in 2 quarters.
Credit Suisse's Mustang Bio position peaked at $57K in Q4 2020.
81 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2022.

Based on Credit Suisse's 13F filing for Q1 2022, filed 16 May 2022.